In vitro and in vivo release of ciprofloxacin from osteoconductive bone defect filler
Authors:
- Tatu J.TJTatu J.
- Minna VeirantoMVMinna Veiranto
- Petteri LankinenPLPetteri Lankinen
- Niko MoritzNMNiko Moritz
- Jari JalavaJJJari Jalava
- Pertti TörmäläPTPertti Törmälä
- Hannu T. AroHAHannu T. Aro
Open Access
- 18 October 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 56 (6) , 1063-1068
Abstract
Objectives: Impregnation of antimicrobial agents within biodegradable carriers with osteoconductive properties could provide the means for one-stage surgical treatment of osteomyelitis. In this study, the in vitro and in vivo antibiotic release from this type of bone defect filler was characterized. Methods: Cylindrical pellets (2.5 × 1.5 mm) were manufactured from bioabsorbable poly(l-lactide-co-glycolide) (PLGA) matrix, ciprofloxacin [8.3 ± 0.1% (w/w)] and osteoconductive bioactive glass microspheres (90–125 μm) [27 ± 2% (w/w)]. In vitro studies were carried out to delineate the release profile of the antibiotic. The antimicrobial activity of the release antibiotic was verified with MIC testing. In a time-sequence study in the rabbit, pellets were surgically implanted in the proximal tibia and the antibiotic concentrations achieved in bone were measured at 1, 2, 3, 4, 5 and 6 months. Results: In vitro elution studies showed sustained release of ciprofloxacin at a therapeutic level (>2 μg/mL) over a time period of 4 months. The released ciprofloxacin had maintained its antimicrobial capacity against five standard ATCC strains. In vivo, the delivery system produced high local bone concentrations (247.9 ± 91.0 μg/g of bone) for a time period of 3 months with no significant systemic exposure. Histomorphometry and micro-CT imaging confirmed new bone formation around the pellets within 3 months as a sign of an independent osteoconductive property of the composite. Conclusions: The tested composite seems to be a promising option for local therapy of surgically treated bone infections. The main advantages are the antibiotic release for a definite time period with therapeutic concentrations, which may minimize slow residual release at suboptimal concentrations.Keywords
This publication has 30 references indexed in Scilit:
- Efficacy of Ciprofloxacin-Releasing Bioabsorbable Osteoconductive Bone Defect Filler for Treatment of Experimental Osteomyelitis Due toStaphylococcus aureusAntimicrobial Agents and Chemotherapy, 2005
- Efficacy of bioabsorbable antibiotic containing bone screw in the prevention of biomaterial-related infection due to Staphylococcus aureusBone, 2005
- Levofloxacin and Trovafloxacin Inhibition of Experimental Fracture-HealingClinical Orthopaedics and Related Research, 2003
- Molecular biologic comparison of new bone formation and resorption on microrough and smooth bioactive glass microspheresJournal of Biomedical Materials Research Part B: Applied Biomaterials, 2003
- Toxic effect of rifampicin on human osteoblast‐like cellsJournal of Orthopaedic Research, 2001
- Effect of ciprofloxacin on the proliferation of osteoblast‐like MG‐63 human osteosarcoma cells in vitroJournal of Orthopaedic Research, 1998
- Dynamic compaction: a new process to compact therapeutic agent-loaded calcium phosphatesBiomaterials, 1997
- Quinolones and OsteomyelitisDrugs, 1995
- Bone and wound fluid concentrations of cephalosporins Oral cefadroxil and parenteral cefuroxime compared in 52 patients with a trochanteric fractureActa Orthopaedica, 1995
- Bioactive CeramicsAnnals of the New York Academy of Sciences, 1988